4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that Robert Fishman, M.D. has joined as Chief Medical Officer & Therapeutic Area Head, Pulmonology; Raphael Schiffmann, M.D. has joined as Senior Vice President & Therapeutic Area Head, Cardiology; and Robert Kim, M.D., M.B.A. has joined as Senior Vice President & Clinical Therapeutic Area Head, Ophthalmology.
"4DMT has made tremendous progress since the close of our Series C financing. We have advanced product candidates across our key therapeutic areas of ophthalmology, cardiology and pulmonology, including the initiation of the clinical programs for 4D-110 and 4D-125 in ophthalmology, and 4D-310 for the treatment of Fabry disease," said David Kirn, M.D., co-founder and chief executive officer of 4DMT. "With the addition of Robert Fishman, Raphael Schiffmann and Robert Kim to our clinical R&D leadership team, 4DMT gains not only extensive experience in clinical development and translational medicine, but also unique and specific experience within each of the initial 4DMT therapeutic areas. We are thrilled to welcome these respected leaders to 4DMT."
Dr. Robert Fishman has over 20 years of experience in product development including both medicines and aerosol-based drug/device combinations. Dr. Fishman was most recently Chief Medical Officer at Xoc Pharmaceuticals, where he led Phase 1 development of drugs for prevention of migraine and treatment of Parkinson’s disease, and prior to that, at Corcept Pharmaceuticals, a publicly traded biopharmaceutical company. Previously, he was Senior Vice President, Clinical Development, at InterMune (acquired by Roche), where he led the final pivotal trial of pirfenidone (Esbriet®) for the treatment of idiopathic pulmonary fibrosis. Before that, at Alexza Pharmaceuticals, he led the Phase 3 studies of inhaled loxapine (ADASUVE), a drug/device combination for the rapid treatment of agitation associated with schizophrenia or bipolar I disorder. Dr. Fishman trained in internal medicine at Deaconess Hospital, Boston, completed a fellowship in pulmonary and critical care medicine at Massachusetts General Hospital, and began his career as a member of the Stanford University pulmonary medicine faculty. He serves as a teaching attending physician in the Stanford pulmonary fellows’ clinic at Palo Alto Veterans Administration Medical Center, and as an advisor to the Stanford SPARK Program in Translational Research. He received an A.B. in Biology from Harvard University and an M.D. from Stanford University School of Medicine.
Dr. Raphael Schiffmann has over 30 years of experience in clinical research, including as an expert on neurometabolic diseases, focusing his research efforts on lysosomal storage disorders. Dr. Schiffmann’s writings include 275 peer-reviewed publications in scholarly journals, and 19 book chapters and reviews. Prior to joining 4DMT, he was the Director of the Institute of Metabolic Disease at the Baylor Research Institute. Before that, Dr. Schiffmann was the lead investigator in the Developmental and Metabolic Neurology Branch at the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH). Dr. Schiffmann has an M.D. degree from the University of Liège, Belgium and a degree of Master of Health Sciences in Clinical Research from Duke University. He is Board Certified in pediatrics and in child neurology and is a Fellow of the American Academy of Neurology.
Dr. Robert Kim has over 20 years of product development experience in ophthalmology. Prior to joining 4DMT, Robert was Chief Medical Officer at Viewpoint Therapeutics, where he led translational development efforts for α-crystallin pharmacologic chaperones. Prior to Viewpoint, he was Chief Medical Officer at Apellis Pharmaceuticals and Vision Medicines. Earlier in his career, Robert was Vice President and Head of Pharmaceutical Product Development at Novartis/Alcon and Vice President of Clinical Ophthalmology at GSK. Dr. Kim began his career in drug development at Genentech, where he managed the Lucentis Phase 3 clinical program through to its first product approval in wet age-related macular degeneration. Dr. Kim received his undergraduate and M.D. degrees from Brown University. Dr. Kim completed his residency in ophthalmology at the University of California, San Francisco (UCSF), post-doctoral training in molecular biology at the National Eye Institute, and retina fellowship training at Moorfields Eye Hospital in London before joining the faculty at UCSF. Dr. Kim also holds an M.B.A. from the Haas School of Business at the University of California, Berkeley.
4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.
4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005763/en/